PATENT CLAIM ANALYSIS

Application Number: 16185125
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["424", "204100"]

Abstract:
Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.

Claim (Index 13):
The method of  claim 1 , wherein the MVA is administered in a dosage of 1\u00d710 8  TCID 50 .

Metadata:
- Claim Count in Document: 7.0
- Percentile: 98.0
- Lexical Diversity: 1.79412
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15662382', '14417779', '15294480', '12505998', '15125388']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.837790270158728
- 35 USC 102 Novelty (BERT): 0.6821723555368128
- Combined Prediction Score: 0.8222284786965365
- Mean Citation Score: 620.094766
- Max Citation Score: 780.5066
- Similarity Product: 666.0973522966863

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test